Patent details

Basic Information

Publication number:

LUC00369

Type:

SPC

SPC Type:

Medical

Basic Patent Number:

EP221814031

Legal Status:

Pending & Published

Application number:

LUC00369

First applicant's nationality:

Procedural language:

French

Marketing Authorization

Marketing Authorization Number:

EU/1/24/1824

Marketing Authorization Type:

Marketing Authorization Date:

18/06/2024

Marketing Authorization Status:

Accepted

Marketing Authorization Country:

Luxembourg (LU)

Dates

Filing date:

11/12/2024

First Marketing Authorization date:

18/06/2024

Grant date:

Activation date:

Publication date:

11/12/2024

Lapsed date:

Expiration date:

Renunciation date:

Revocation date:

Annulment date:

Basic SPC Expiration:

18/06/2039

SPC Extension Expiration:

18/06/2039

Rejection date:

Withdrawal date:

Owner

From:

11/12/2024

 

 

Name:

Bioverativ Therapeutics Inc.

Address:

225 Second Avenue, Waltham MA 02451, United States (US)

Agent

Name:

OFFICE FREYLINGER S.A.

From:

11/12/2024

Address:

Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)

To:

Publication

Bulletin

Bulletin Heading:

SPC1

Bulletin edition number:

2025/01

Publication date:

06/01/2025

Description:

Section C : Published requests for Supplementary Protection Certificates – I1 publication

Annual Fees

Annual Fee Due Date:

31/01/2035

Annual Fee Number:

21

Annual Fee Amount:

410 Euro

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages
11/12/2024	Summary of the product caracteristics	66
11/12/2024	Marketing authorization	4
11/12/2024	Marketing authorization	3
11/12/2024	MA publication	11
11/12/2024	Application Form	3
11/12/2024	Outgoing Correspondence	1
11/12/2024	Publication	1